Related Experiment Video
Updated: Aug 9, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Conditional survival of patients with diffuse large B-cell lymphoma
Michael B Moller1, Niels T Pedersen, Bjarne E Christensen
1Department of Pathology, Odense University Hospital, Odense, Denmark. michael.boe.moeller@ouh.fyns-amt.dk
Cancer
|April 6, 2006
Summary
Conditional survival estimates offer more accurate prognosis for diffuse large B-cell lymphoma (DLBCL) patients who have already survived initial treatment. Prognostic factors like the International Prognostic Index (IPI) lose significance over time, with age becoming the primary predictor.
Area of Science:
- Hematology
- Oncology
- Biostatistics
Background:
- Lymphoma prognosis traditionally relies on the International Prognostic Index (IPI) assessed at diagnosis.
- Conditional survival estimates, considering patients who have already survived post-treatment, offer more clinically relevant prognostic insights.
- Conditional survival data for lymphoma patients remain largely unreported.
Purpose of the Study:
- To estimate conditional survival for diffuse large B-cell lymphoma (DLBCL) patients.
- To evaluate the changing prognostic impact of the IPI and its components over time.
- To identify key prognostic factors for DLBCL patients surviving beyond initial treatment.
Main Methods:
- Utilized data from 1209 DLBCL patients from the Danish Lymphoma Group's LYFO registry.
- Applied the Kaplan-Meier method to calculate conditional survival probabilities from 0-5 years post-diagnosis.
- Conducted multivariate analysis on patients surviving three or more years.
Main Results:
- Conditional survival probability increases significantly in the first three years post-diagnosis, then plateaus.
- Median survival for DLBCL patients increases substantially when conditioned on surviving 3-5 years (108-120 months vs. 38 months overall).
- The prognostic value of the IPI diminishes over time; only age retains significant prognostic impact after two years.
Conclusions:
- Conditional survival probability provides more accurate prognostic information for DLBCL patients who have survived at least one year post-diagnosis compared to conventional estimates.
- Age emerges as the sole significant prognostic factor for DLBCL patients surviving three or more years.
- These findings highlight the evolving nature of prognostic factors in DLBCL and the utility of conditional survival analysis.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:16Primary Lymphoid Organs
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...